Fresenius Kabi Introduces Leucovorin Calcium Injection, USP

Fresenius Kabi’s LeucovorinCalcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination, is now available in the U.S.
 
Leucovorin Calcium is also used as a rescue drug after high-dose methotrexate therapy in osteosarcoma, in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, and in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
 
Fresenius Kabi Leucovorin Calcium Injection, USP is available in 10 mg per mL single-use vials, 100 mg per 10 mL and 500 mg per 50 mL strengths.  This is the only liquid presentation of Leucovorin available in the U.S.
  
“At Fresenius Kabi we are dedicated to finding safe and affordable solutions for health care providers,” said John Ducker, president and chief executive officer of Fresenius Kabi USA. “We are pleased to offer a version of Leucovorin Calcium Injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication.”